Portal de Periódicos da CAPES

The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome

2007; Springer Nature; Volume: 32; Issue: 3 Linguagem: Inglês

10.1007/s12016-007-8005-6

1559-0267

Jiska Meijer, Justin Pijpe, Hendrika Bootsma, Arjan Vissink, Cees G. M. Kallenberg,

Diabetes and associated disorders

The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjögren's syndrome (SS) and the current availability of various biological agents (anti-TNF-α, IFN- α, anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention. In SS, various phase I and II studies have been performed to evaluate these new strategies. Currently, B cell-directed therapies seem to be more promising than T cell-related therapies. However, large, randomized, placebo-controlled clinical trials are needed to confirm the promising results of these early studies. When performing these trials, special attention has to be paid to prevent the occasional occurrence of the severe side effects.